Acellular Pertussis Completed Phase 3 Trials for Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (DB10788)

IndicationStatusPhase
DBCOND0031302 (Acellular Pertussis)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00385255Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in AdultsPrevention
NCT00346073Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 YearsPrevention
NCT02096263Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy InfantsPrevention